Irschick E U, Hladik F, Niederwieser D, Nussbaumer W, Holler E, Kaminski E, Huber C
Department of Internal Medicine, University of Innsbruck, Austria.
Blood. 1992 Mar 15;79(6):1622-8.
Previous studies demonstrated that the frequency of donor-versus-host-reactive cytotoxic T-cell precursors (CTL-p) before allogeneic bone marrow transplantation (BMT) from matched unrelated donors correlates with the incidence of graft-versus-host disease (GvH-D). We investigated whether clinical manifestations of GvH-D after HLA-identical sibling BMT are accompanied by an increased frequency of minor histocompatibility antigen (HA)-specific CTL-p. We further asked whether changes of third-party-reactive CTL-p as a measure of overall immunocompetence are related to infectious complications frequently seen immediately after BMT. Eighteen patients (16 with an HLA-identical bone marrow graft, two with either one HLA-A or one HLA-DR mismatch) were studied. Limiting dilution analysis (LDA) was used to assess donor CTL-p frequencies against recipient pre-BMT, donor, and third-party targets in a follow-up study. Eight cases receiving HLA-identical marrow grafts never developed signs of GvH-D. Undetectable or very low frequencies (1/131,458) of minor HA-specific CTL-p were demonstrated pre-BMT. Two recipients, one of an HLA-A- and one of an HLA-DR-mismatched graft, exhibited low frequencies of recipient-specific CTL-p (1/66,920 and 1/85,577, respectively) before transplantation, which further decreased despite mild GvH-D grade I, or decreased within 3 months after grafting in the other case. Eight patients receiving HLA-identical grafts developed GvH-D. Recipient-specific CTL-p were less than 1/300,000 in five patients during limited GvH-D (four with grade I and one with grade II disease of the skin), but were detectable in three patients presenting with extensive GvH-D grades II to III and ranged from 1/7,993 to 1/210,108. The differences in post-BMT recipient-specific CTL-p frequencies between patients with GvH-D grades 0 to I (median, less than 1/300,000) and those with GvH-D grades II to III (median, 1/111,970) were statistically significant (P less than .05). Posttransplant lymphocytes from all 18 patients contained less than 1/300,000 CTL-p with specificity for donor targets. Comparison of third-party-reactive CTL-p frequencies between donor and post-BMT recipient lymphocytes showed a severe and long-lasting depletion subsequent to BMT, which was not related to infectious complications. Again, these differences reached the level of statistical significance (median CTL-p before BMT, 1/4,417; after BMT, 1/14,289; P less than .005).(ABSTRACT TRUNCATED AT 400 WORDS)
先前的研究表明,来自匹配无关供者的异基因骨髓移植(BMT)前供者抗宿主反应性细胞毒性T细胞前体(CTL-p)的频率与移植物抗宿主病(GvH-D)的发生率相关。我们调查了 HLA 相同的同胞 BMT 后 GvH-D 的临床表现是否伴有次要组织相容性抗原(HA)特异性 CTL-p 频率的增加。我们还进一步询问,作为整体免疫能力指标的第三方反应性 CTL-p 的变化是否与 BMT 后立即常见的感染并发症有关。研究了 18 例患者(16 例接受 HLA 相同的骨髓移植,2 例 HLA-A 或 HLA-DR 有一个位点不匹配)。在一项随访研究中,采用极限稀释分析(LDA)评估供者 CTL-p 针对移植前受者、供者和第三方靶标的频率。8 例接受 HLA 相同骨髓移植的患者从未出现 GvH-D 的迹象。移植前未检测到或仅显示极低频率(1/131,458)的次要 HA 特异性 CTL-p。两名受者,一名接受 HLA-A 不匹配移植,一名接受 HLA-DR 不匹配移植,移植前显示受体特异性 CTL-p 频率较低(分别为 1/66,920 和 1/85,577),尽管有轻度 I 级 GvH-D,但频率进一步降低,或在另一例中移植后 3 个月内降低。8 例接受 HLA 相同移植的患者发生了 GvH-D。在局限性 GvH-D 期间,5 例患者的受体特异性 CTL-p 小于 1/300,000(4 例为 I 级皮肤疾病,1 例为 II 级皮肤疾病),但在 3 例出现广泛 II 至 III 级 GvH-D 的患者中可检测到,范围为 1/7,993 至 1/210,108。GvH-D 0 至 I 级患者(中位数,小于 1/300,000)与 GvH-D II 至 III 级患者(中位数,1/111,970)移植后受体特异性 CTL-p 频率的差异具有统计学意义(P 小于 0.05)。所有 18 例患者移植后的淋巴细胞中,针对供者靶标的 CTL-p 均小于 1/300,000。比较供者和 BMT 后受者淋巴细胞中第三方反应性 CTL-p 频率,发现 BMT 后出现严重且持久的耗竭,这与感染并发症无关。同样,这些差异达到了统计学意义水平(BMT 前 CTL-p 中位数为 1/4,417;BMT 后为 1/14,289;P 小于 0.005)。(摘要截短于 400 字)